RxDoctor Payments Data

Laura Rivers, MD

Rheumatology · New Orleans, LANPI 1861984437

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Amgen at 29.3% of the total. 2025 is the largest year on record at $1,894, 7.4 times the $255 reported in 2021. That places this record below the midpoint for rheumatology clinicians in LA, where the typical reported total is $8,351.

$6,394in general payments, 2019–2025

Across 218 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Johnson & Johnson$534
  • Boehringer Ingelheim$342
  • UCB, Inc.$334
  • E.r. Squibb & Sons, L.L.C.$213
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,23497%
  • Education$1603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,394 in reported general payments places this provider in the 35th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$173,769
Medicare patients
269
Services billed
14,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MethotrexateMethotrexate Sodium191$4,640
Leflunomide90$4,474
Hydroxychloroquine Sulfate117$3,237
Mycophenolate Mofetil39$2,117
Prednisone191$1,332
Colchicine26$1,328
Sulfasalazine34$392
Methylprednisolone48$310
Celecoxib27$208
Meloxicam64$203
Pilocarpine Hcl11$167
Gabapentin20$136
Folic Acid26$129
Pregabalin17$112
Tramadol Hcl21$102

Paid to pharmacies, not to this prescriber.

Other rheumatology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →